# A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

> **NCT04187300** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 68 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT04187300
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-16
- **Primary completion:** 2020-09-23
- **Final completion:** 2020-09-23
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04187300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04187300, "A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04187300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*